In June, the Centers for Medicare & Medicaid Services released is much-anticipated proposal to offer "transitional coverage for emerging technologies." The rule purports to offer an expedited pathway to Medicare coverage for certain medical devices. On July 27th, Matt Wetzel, Partner, Life Sciences, at Goodwin Procter hosted a webinar to break down the so-called TCET rule and what it means for medical technology companies with breakthrough designation.
Webinar Presentation Materials
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
